US FDA accepts Flutiform NDA
This article was originally published in Scrip
SkyePharma is one step closer to US approval for its lead development product, the combination asthma therapy Flutiform (fluticasone propionate plus formoterol fumarate).
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.